C7orf38 Inhibitors
C7orf38 inhibitors encompass a specialized category of chemical compounds designed to selectively interfere with the function of the protein encoded by the C7orf38 gene, a locus on chromosome 7 open reading frame 38. The precise mechanisms through which these inhibitors act are predicated on the understanding of the protein's role within cellular processes, which remains to be fully elucidated. However, scientific inference suggests that these inhibitors may work by disrupting the protein's interaction with other molecular entities within the cell, thereby impeding its normal function. The putative activities of C7orf38 involve a spectrum of biochemical pathways, and thus, the inhibitors are tailored to target these specific interactions. The chemical structures within this class are diverse, yet they share the commonality of being designed to bind to the active site or allosteric sites of C7orf38, or to interfere with its expression levels by modulating the gene's transcriptional activity.
The inhibitory action of these compounds is grounded in their capacity to either prevent the protein from fulfilling its role in the pathway it is involved in or by altering the protein's structure to an extent that its activity is diminished or nullified. The design of C7orf38 inhibitors is a sophisticated endeavor that often involves high-throughput screening, structure-activity relationship studies, and computational modeling to predict and confirm their binding affinities and functional impacts. The assumption is that by inhibiting C7orf38, the compounds indirectly influence the cellular pathways in which the protein is implicated. The exact nature of these pathways is subject to ongoing research, but they are believed to involve a range of cellular functions from signal transduction to gene expression regulation. The specificity of C7orf38 inhibitors is crucial, as it minimizes off-target effects and ensures that the inhibition is as localized as possible to the intended protein's function, preserving overall cellular homeostasis while achieving the desired inhibition.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can impede the mTOR pathway, which is critical for protein synthesis and cell growth. By inhibiting this pathway, rapamycin reduces the cellular processes necessary for the functional activity of C7orf38, assuming that C7orf38 is involved in similar cellular processes regulated by the mTOR pathway. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Given that C7orf38's function may be regulated by phosphorylation, staurosporine could indirectly decrease C7orf38 activity by inhibiting the kinases responsible for its activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that disrupts the PI3K/Akt signaling pathway. By inhibiting this pathway, it could lead to a decrease in the phosphorylation events that may be required for C7orf38 activity, given that this protein is part of or influenced by the PI3K/Akt pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. It alters chromatin structure and gene expression. If C7orf38 expression is regulated by histone acetylation, Trichostatin A could indirectly decrease its expression and thereby its functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which blocks the MAPK/ERK pathway. If C7orf38 is a downstream effector of this pathway, inhibiting MEK could lead to decreased activation of C7orf38 by preventing its necessary phosphorylation or by reducing the expression of upstream activators of C7orf38. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor and could reduce C7orf38 activity by inhibiting the stress-activated MAPK pathways that may be involved in the regulation or activation of C7orf38. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is part of the MAPK family. If C7orf38 is regulated by JNK-mediated signaling, then SP600125 could indirectly decrease C7orf38 activity by blocking this pathway. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
WZB117 inhibits GLUT1, which could decrease glucose uptake and reduce energy supply in cells. If C7orf38 function is energy-dependent, inhibiting GLUT1 could indirectly decrease its activity by limiting the cellular energy available for its function. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose is a glycolysis inhibitor and can inhibit glucose metabolism. If C7orf38 activity requires energy from glycolysis, this compound could indirectly lead to decreased functional activity of C7orf38 by limiting ATP production, which is necessary for many cellular processes. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus and protein trafficking. If C7orf38 relies on protein trafficking for its function or localization, Brefeldin A might decrease its functional activity by inhibiting proper trafficking and processing. | ||||||